MenAfriVac
MenAfriVac
MenAfriVac (== Template:IPA ==
The Template:IPA (International Phonetic Alphabet) is a system of phonetic notation based primarily on the Latin alphabet. It was devised by the International Phonetic Association in the late 19th century as a standardized representation of the sounds of spoken language.
Pronunciation
The pronunciation of the term "IPA" is /aɪ piː eɪ/ in English.
Etymology
The term "IPA" is an acronym for the International Phonetic Alphabet. The International Phonetic Association, founded in 1886, created the IPA to provide a single, universal system for the transcription of spoken language.
Related Terms
- Phonetic notation: A system used to visually represent the sounds of speech. The IPA is one type of phonetic notation.
- Phonetics: The study of the physical sounds of human speech. It is concerned with the physical properties of speech sounds (phonemes), and the processes of their physiological production, auditory reception, and neurophysiological perception.
- Phonology: The study of the way sounds function within a particular language or languages. While phonetics concerns the physical production, acoustic transmission and perception of the sounds of speech, phonology describes the way sounds function within a particular language or languages.
- Transcription (linguistics): The systematic representation of spoken language in written form. The source of the words transcribe and transcription, the term means "to write across" in Latin, and it's the process of converting spoken language into written form. In linguistics, this is often done using the IPA.
External links
- Medical encyclopedia article on MenAfriVac
- Wikipedia's article - MenAfriVac
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski) is a vaccine specifically designed to combat Neisseria meningitidis serogroup A, a bacterium that causes meningitis.
Etymology
The term "MenAfriVac" is a portmanteau of "Meningitis", "Africa", and "Vaccine". It signifies the vaccine's purpose, which is to prevent meningitis in Africa.
History
MenAfriVac was developed by the Meningitis Vaccine Project (MVP), a partnership between the World Health Organization (WHO) and the non-profit organization PATH. The development of MenAfriVac was in response to the recurring meningitis epidemics in Africa's "meningitis belt", a region that stretches from Senegal in the west to Ethiopia in the east.
Usage
MenAfriVac is administered via injection and is primarily used in the sub-Saharan African countries that make up the "meningitis belt". It is the first vaccine to gain approval from the WHO for use in a controlled temperature chain (CTC), meaning it can be kept at temperatures up to 40°C for up to four days.
Effectiveness
Since its introduction in 2010, MenAfriVac has significantly reduced the incidence of meningitis A in the countries where it has been used. It is estimated to have prevented approximately 1 million cases of meningitis A and saved tens of thousands of lives.
Related Terms
External links
- Medical encyclopedia article on MenAfriVac
- Wikipedia's article - MenAfriVac
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski